"label","name","id","rationale","instanceType","description","uuid:ID"
"","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","The main design for the study","4477cca7-5244-45a9-8104-2ab6ec43ad51"
